The WHO projects that by 2030 there will be a shortfall of 10 million healthcare workers, which is further aggravated by escalating costs of care outpacing economic growth in most countries. Ufonia has developed Dora, the first UKCA-marked, artificial intelligence enabled, automated, clinical voice assistant to radically increase the volume of care that can be delivered. By automating routine outpatient appointments, Ufonia's Dora platform can reduce the need for clinician-led care by about 65%, which can materially impact the number of patients that can be seen and cared for and allow more responsive and personalised care.
Dr Theodora Ephson is the Commercial Director with responsibility for defining strategy for market access and growing the number of patients the product reaches. She notes that Ufonia: “are at an important inflection point and having recently been promoted to Director the accelerator will be important for me to be successful in my new role.”
One area where she sees the Shott Scale Up Accelerator as pivotal is in growing in confidence as a leader. She recognises that the 1:1 coaching will help to: “develop my leadership and management skills and build my confidence in autonomously making impactful decisions for our business.”
Dora for has been rigorously evaluated for safety and effectiveness in clinical settings and demonstrated product–market fit for one use case in the UK, cataract surgery. Ufonia are now poised for rapid scale up, with a five-year plan to have Dora making an impact across multiple high volume care pathways and on multiple continents. Over the next 12 months they will focus on scaling in the UK with their first use case before they continue to scale Dora across new use cases in the UK. They will also continue to build their body of research and clinical evidence to support this.
